Richard Lafayette

1 week ago | ajmc.com | Maggie L. Shaw |Richard Lafayette

On April 2, atrasentan (Vanrafia; Novartis) received an accelerated approval from the FDA for proteinuria reduction in primary immunoglobulin A (IgA) nephropathy, becoming the second “first and only” therapy approved for this purpose in the past month—following iptacopan (Fabhalta) for C3 glomerulopathy on March 20.1,2 This approval of the endothelin A receptor antagonist was based on a prespecified interim analysis of the phase 3 ALIGN study (NCT04573478), which is comparing the efficacy and...